Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tagmokitug · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mCRPC: Tagmokitug + Pasritamig | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Tagmokitug | DRUG | Specified dose on specified days. |
| Pasritamig | DRUG | Specified dose on specified days. |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except f...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |